Pharmacology Of Potential Anti-Tumour Agents: Iron Chelators Of The BpT Class
Funder
National Health and Medical Research Council
Funding Amount
$585,455.00
Summary
Pharmacology of Potential Anti-Tumour Agents: Iron Chelators of the BpT Class Cancer cells have a high iron requirement for DNA synthesis and many clinical trials showed Fe chelators are effective anti-cancer drugs. Their potential to act as anti-tumour agents has been confirmed by the entrance of Triapine into widespread NCI clinical trials. In this NHMRC Renewal, we will perform pharmacological and preclinical studies to promote the development of BpT chelators as novel anti-tumour agents.
Stewarding thin markets: improving public sector market effectiveness. This project aims to develop methodologies to identify thin markets in the public service sector. Thin markets, where there are a low number of buyers or low number of sellers, are a major risk for governments utilising a personalised approach to service delivery. This project will develop new methodologies for identifying thin markets and determine ways emerging markets can be stewarded to better achieve their aims.